Published: 22 October 2025
Safety Information
Monitoring communication
Estradot (estradiol) transdermal patches: reports of quality and efficacy
concerns
22 October 2025
Medsafe is aware of quality and efficacy concerns from consumers associated with the use of Estradot (estradiol) patches. These concerns include:
- return of menopausal symptoms
- issues with patch adhesion.
Medsafe's initial investigation has not identified any product quality issues that explain the adhesion or lack of efficacy issues.
Sandoz, the sponsor of the patches, has investigated this issue and will communicate the outcome with relevant healthcare professionals. We have published this letter on the Dear Healthcare Professionals section of our website.
Products affected
More information
Medsafe's actions
Reporting
Products affected
| Product name | Sponsor |
|---|---|
| Estradot 25mcg/24hrs patch | Sandoz |
| Estradot 50mcg/24hrs patch | Sandoz |
| Estradot 75mcg/24hrs patch | Sandoz |
| Estradot 100mcg/24hrs patch | Sandoz |
More information
Estradot (estradiol) is indicated as estrogen replacement therapy for menopause symptoms and prevention of postmenopausal osteoporosis.
The sponsor's investigation found that the products met all quality specifications. The sponsor tested samples from multiple batches (including batch 96622) and confirmed that the patches were within specifications. Similarly, the sponsor did not find any problems in the manufacturing or packaging processes. Note that the manufacturer of this product has not changed.
The sponsor emphasises the importance of applying the patches correctly. The package insert contains detailed instructions, including proper skin preparation and where and how to apply the patch. The letter to healthcare professionals also contains a copy of these instructions.
Not all medicines work for all people. If you are experiencing difficulties, please go back to your doctor to discuss other treatment options.
See also the Estradot (estradiol) consumer medicine information for more information about this medicine, including the known side effects.
Medsafe's actions
We are continuing to work with the company while monitoring any further reports.
Reporting
Please report quality issues with this medicine to:
- Medsafe via email: recalls@health.govt.nz
- Sandoz via email: mi.new_zealand@sandoz.com or phone: 0800-SANDOZ (0800 726 369).





